

## Info Sheet for Technical description

No. 0014

### Organization

\* Mandatoty fields

Name of Organization*	C4U Corporation	
Address, City, States, Zip, Country*	Yamadaoka 2-8, Suita, Osaka, 565-0871, JAPAN	
URL	<a href="https://www.crispr4u.jp/en/">https://www.crispr4u.jp/en/</a>	
Brief Descriptions of Organization* (Approx. 100 words)	C4U is a biotechnology venture company from Osaka University, engaging in research and development of novel genome editing technology, CRISPR-Cas3. Utilizing newly invented cutting-edge genome editing technology, C4U promotes the development of new treatments for various diseases, including genetic diseases. C4U also collaborates with other companies and is working to develop platforms for applications in other industries.	
Contact address	Name*	Katsu Akiyama / Kohei Kishi
	Department* / Position	Business Development Div.
	E-mail* / TEL	<a href="mailto:akiyama@crispr4u.com">akiyama@crispr4u.com</a> / +81-80-4651-3645 <a href="mailto:k.kishi@crispr4u.com">k.kishi@crispr4u.com</a> / +81-80-4384-9466

### What kind of technology do you want to offer? \*

- A.** Clinical Development Pipelines → Please see **Sheet [A]**
  - B.** Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Services etc. → Please see **Sheet [B]**
  - C.** Platform Technologies(\*) that are not included in the above (Group B) → Please see **Sheet [C]**
- \* Peripheral technologies that contribute to a significant improvement in productivity throughout the value chain of pharmaceuticals, from research and development to manufacturing and ultimately market launch.

### If you agree to the following, please check "Yes" below. \*

The technologies introduced in this 'Info Sheet' are in the public domain, as they have been published in research papers or have related patent applications.

- Yes

### Do you have any collaborations/partnerships with pharmaceutical companies?

- Yes
- No

### If you have already received funding from VCs or other sources, up to which stage has the investment round progressed?

- Angel / Seed (including AMED/JST grants)
- Series A
- Series B
- Series C
- Series D or further advanced stages

### Do you agree to leave your presentation materials at FIRM hands and entrust us to make use of them for the purpose of promoting your partnering opportunities? \*

Options*	Comments
<input checked="" type="checkbox"/> Yes	
<input type="checkbox"/> No	

Filled in by\*

Date\*

Kohei Kishi
2024/9/3

**Sheet [C]** Platform Technologies *that are not included in Group B***Info Sheet for Technical overview**

No. 0014

\* Mandatoty fields

**Title\*****CRISPR-Cas3 – Novel gene editing platform by C4U Corporation****Description\***

C4U Corporation ("C4U") has an exclusive license of a novel gene editing platform, CRISPR-Cas3, from Osaka University. CRISPR-Cas3 has different profiles from well-known CRISPR-Cas9 as below;

- 1) Off-target (undesired) deletion has not been detected yet due to higher specificity of the longer crRNA of CRISPR-Cas3 than that of Cas9,
- 2) Larger portion of gene can be deleted while Cas9 has a point cut ability, and
- 3) Cas3 patent families are independent from Cas9 patents and there is no umbrella patent between Cas3 and Cas9.

These unique profiles can differentiate CRISPR-Cas3 from other gene editing technologies, and C4U has executed several collaboration agreements with pharma companies as well as biotech companies. In addition of a healthcare sector, CRISPR-Cas3 can be used for agriculture and aquaculture sectors and C4U has some collaborations in those fields as well.

C4U is looking for global and regional partners who would like to utilize our CRISPR-Cas3 into their research program and platform to generate pipeline products in various fields.

**Filled in by\***

Kohei Kishi

**Date\***

3-Sep-24